WO1994024144A3 - Enhanced triple-helix and double-helix formation with oligomers containing modified purines - Google Patents

Enhanced triple-helix and double-helix formation with oligomers containing modified purines Download PDF

Info

Publication number
WO1994024144A3
WO1994024144A3 PCT/US1994/004013 US9404013W WO9424144A3 WO 1994024144 A3 WO1994024144 A3 WO 1994024144A3 US 9404013 W US9404013 W US 9404013W WO 9424144 A3 WO9424144 A3 WO 9424144A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligomers
helix
double
triplexes
oligomers containing
Prior art date
Application number
PCT/US1994/004013
Other languages
French (fr)
Other versions
WO1994024144A2 (en
Inventor
Brian Froehler
Mark Matteucci
Original Assignee
Gilead Sciences Inc
Brian Froehler
Mark Matteucci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Brian Froehler, Mark Matteucci filed Critical Gilead Sciences Inc
Priority to AU66320/94A priority Critical patent/AU6632094A/en
Priority to EP94914131A priority patent/EP0695306A1/en
Publication of WO1994024144A2 publication Critical patent/WO1994024144A2/en
Publication of WO1994024144A3 publication Critical patent/WO1994024144A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain 7-deaza-7-substituted purines or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used as pharmaceutical agents to treat various diseases such as those caused by viruses and can be used for diagnostic purposes in order to detect viruses or disease conditions.
PCT/US1994/004013 1993-04-19 1994-04-12 Enhanced triple-helix and double-helix formation with oligomers containing modified purines WO1994024144A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU66320/94A AU6632094A (en) 1993-04-19 1994-04-12 Enhanced triple-helix and double-helix formation with oligomers containing modified purines
EP94914131A EP0695306A1 (en) 1993-04-19 1994-04-12 Enhanced triple-helix and double-helix formation with oligomers containing modified purines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5069893A 1993-04-19 1993-04-19
US08/050,698 1993-04-19

Publications (2)

Publication Number Publication Date
WO1994024144A2 WO1994024144A2 (en) 1994-10-27
WO1994024144A3 true WO1994024144A3 (en) 1995-03-16

Family

ID=21966852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/004013 WO1994024144A2 (en) 1993-04-19 1994-04-12 Enhanced triple-helix and double-helix formation with oligomers containing modified purines

Country Status (3)

Country Link
EP (1) EP0695306A1 (en)
AU (1) AU6632094A (en)
WO (1) WO1994024144A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
DE4438918A1 (en) 1994-11-04 1996-05-09 Hoechst Ag Modified oligonucleotides, their preparation and their use
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
US6331617B1 (en) 1996-03-21 2001-12-18 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
US6274313B1 (en) 1996-03-21 2001-08-14 Pioneer-Hybrid International, Inc. Oligonucleotides with cationic phosphoramidate internucleoside linkages and methods of use
US5734040A (en) * 1996-03-21 1998-03-31 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
WO1998000433A1 (en) * 1996-07-03 1998-01-08 President And Fellows Of Harvard College Template-directed interference footprinting of protein-adenine contacts
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
DE19842527A1 (en) * 1998-09-18 2000-03-23 Friedrich Schiller Uni Jena Bu Formation of a triple helix forming oligomer comprises searching for a cytosine and/or adenine-rich region of a double-stranded DNA
EP1263773A4 (en) 2000-03-14 2005-08-31 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US7070933B2 (en) 2001-09-28 2006-07-04 Gen-Probe Incorporated Inversion probes
US7144868B2 (en) 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1682564A1 (en) 2003-10-27 2006-07-26 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES
KR20060096487A (en) 2003-10-27 2006-09-11 진랩스 테크놀러지스, 인크. Nucleoside compounds for treating viral infections
US7202223B2 (en) 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
NZ546201A (en) 2003-10-27 2009-05-31 Genelabs Tech Inc Nucleoside compounds for treating viral infections
WO2008017473A2 (en) 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
CA2691364C (en) 2007-06-19 2020-06-16 Stratos Genomics, Inc. High throughput nucleic acid sequencing by expansion
WO2009035438A1 (en) * 2007-09-13 2009-03-19 Janos Borbely Polymeric nanoparticles by ion-ion interactions
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
WO2010088557A1 (en) 2009-01-29 2010-08-05 Stratos Genomics Inc. High throughput nucleic acid sequencing by expansion and related methods
TW201102390A (en) 2009-03-31 2011-01-16 Arqule Inc Substituted pyrazolo-pyrimidine compounds
US8586301B2 (en) 2010-06-30 2013-11-19 Stratos Genomics, Inc. Multiplexed identification of nucleic acid sequences
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US9212392B2 (en) 2012-09-25 2015-12-15 Exact Sciences Corporation Normalization of polymerase activity
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014152937A1 (en) 2013-03-14 2014-09-25 Ibis Biosciences, Inc. Nucleic acid control panels
US10301345B2 (en) 2014-11-20 2019-05-28 Stratos Genomics, Inc. Phosphoroamidate esters, and use and synthesis thereof
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
EP3998353A1 (en) 2015-10-30 2022-05-18 Exact Sciences Corporation Multiplex amplification detection assay and isolation and detection of dna from plasma
EP3904528A1 (en) 2015-11-16 2021-11-03 Stratos Genomics Inc. Dp04 polymerase variants
CN109563546B (en) 2016-05-05 2022-09-09 精密科学发展有限责任公司 Detection of lung tumors by analysis of methylated DNA
JP7289264B2 (en) 2017-01-27 2023-06-09 エグザクト サイエンシーズ コーポレーション Detection of Colon Tumors by Analysis of Methylated DNA
EP3619321A4 (en) 2017-05-04 2020-10-28 Stratos Genomics Inc. Dp04 polymerase variants
KR20240011880A (en) 2017-12-07 2024-01-26 에모리 유니버시티 N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2018383610A1 (en) 2017-12-11 2020-07-23 F. Hoffmann-La Roche Ag DPO4 polymerase variants with improved accuracy
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
GB2605952A (en) * 2021-04-12 2022-10-26 Stealth Labels Biotech Ab Fluorescent nucleoside triphosphates
US20220403450A1 (en) 2021-06-03 2022-12-22 Illumina Software, Inc. Systems and methods for sequencing nucleotides using two optical channels
CA3223131A1 (en) 2021-07-01 2023-01-05 Rean Silke MUSA Device having horizontal nanochannel for nanopore sequencing
WO2023034079A1 (en) 2021-09-01 2023-03-09 Illumina Software, Inc. Amplitude modulation for accelerated base calling
AU2022349615A1 (en) 2021-09-22 2024-01-18 Illumina, Inc. Sequencing polynucleotides using nanopores
US20230112203A1 (en) 2021-09-30 2023-04-13 Illumina, Inc. Isolation of cells in a nanopore sensor array
WO2023086391A1 (en) 2021-11-15 2023-05-19 Illumina, Inc. Nanopore systems and methods of fabrication
US20230183799A1 (en) 2021-12-10 2023-06-15 Illumina, Inc. Parallel sample and index sequencing
WO2023175021A1 (en) 2022-03-15 2023-09-21 Illumina, Inc. Methods of preparing loop fork libraries
US20230357307A1 (en) 2022-05-04 2023-11-09 Illumina, Inc. Cleavable cyclic loop nucleotides for nanopore sequencing
WO2023239660A1 (en) 2022-06-07 2023-12-14 Illumina Software, Inc. Methods and systems for identifying gene variants
WO2024010809A2 (en) 2022-07-07 2024-01-11 Illumina Software, Inc. Methods and systems for detecting recombination events
WO2024010812A2 (en) 2022-07-07 2024-01-11 Illumina Software, Inc. Methods and systems for determining copy number variant genotypes

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3309358A (en) * 1965-09-20 1967-03-14 Upjohn Co 7-deazaadenine 2', 5'-and 3', 5'-dinucleoside phosphate and process therefor
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US3962211A (en) * 1975-01-13 1976-06-08 The University Of Utah 7-substituted nucleoside compounds
EP0021293A2 (en) * 1979-06-14 1981-01-07 The Wellcome Foundation Limited 4-Substituted thio-1-beta-D-ribofuranosylpyrazolo(3,4-D) pyrimidines, processes for their preparation, pharmaceutical formulations and medical uses
EP0057548A2 (en) * 1981-01-29 1982-08-11 Warner-Lambert Company 7-Beta-D-arabinofuranosyl-7H-pyrrolo(2,3-d)pyrimidine-4-amine 5'-phosphate compounds useful as antiviral agents, pharmaceutical compositions containing the compounds, and processes for producing the compounds
EP0251786A2 (en) * 1986-07-02 1988-01-07 E.I. Du Pont De Nemours And Company Alkynylamino-nucleotides
EP0286028A2 (en) * 1987-04-10 1988-10-12 Roche Diagnostics GmbH Derivatives of disazapurine nucleosides, process for their preparation and their use in the sequence analysis of nucleic acids and as antiviral agents
WO1989012060A1 (en) * 1988-06-06 1989-12-14 Steven Albert Benner Oligonucleotide analogs containing sulfur
WO1989012380A2 (en) * 1988-06-09 1989-12-28 Temple University Of The Commonwealth System Of Hi Therapeutic uses of 2',5'-oligoadenylate derivatives
WO1990003370A1 (en) * 1988-09-28 1990-04-05 Microprobe Corporation DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
EP0450102A1 (en) * 1989-10-26 1991-10-09 Yamasa Shoyu Kabushiki Kaisha Nucleoside derivative
WO1993003736A1 (en) * 1991-08-21 1993-03-04 Microprobe Corporation Cross-linking oligonucleotides for enzyme-mediated triple strand formation
WO1993009127A1 (en) * 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
WO1993012130A1 (en) * 1991-12-09 1993-06-24 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosines, isoster analogues and isoguanosine derivates and their use

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3309358A (en) * 1965-09-20 1967-03-14 Upjohn Co 7-deazaadenine 2', 5'-and 3', 5'-dinucleoside phosphate and process therefor
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US3962211A (en) * 1975-01-13 1976-06-08 The University Of Utah 7-substituted nucleoside compounds
EP0021293A2 (en) * 1979-06-14 1981-01-07 The Wellcome Foundation Limited 4-Substituted thio-1-beta-D-ribofuranosylpyrazolo(3,4-D) pyrimidines, processes for their preparation, pharmaceutical formulations and medical uses
EP0057548A2 (en) * 1981-01-29 1982-08-11 Warner-Lambert Company 7-Beta-D-arabinofuranosyl-7H-pyrrolo(2,3-d)pyrimidine-4-amine 5'-phosphate compounds useful as antiviral agents, pharmaceutical compositions containing the compounds, and processes for producing the compounds
EP0251786A2 (en) * 1986-07-02 1988-01-07 E.I. Du Pont De Nemours And Company Alkynylamino-nucleotides
EP0286028A2 (en) * 1987-04-10 1988-10-12 Roche Diagnostics GmbH Derivatives of disazapurine nucleosides, process for their preparation and their use in the sequence analysis of nucleic acids and as antiviral agents
WO1989012060A1 (en) * 1988-06-06 1989-12-14 Steven Albert Benner Oligonucleotide analogs containing sulfur
WO1989012380A2 (en) * 1988-06-09 1989-12-28 Temple University Of The Commonwealth System Of Hi Therapeutic uses of 2',5'-oligoadenylate derivatives
WO1990003370A1 (en) * 1988-09-28 1990-04-05 Microprobe Corporation DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
EP0450102A1 (en) * 1989-10-26 1991-10-09 Yamasa Shoyu Kabushiki Kaisha Nucleoside derivative
WO1993003736A1 (en) * 1991-08-21 1993-03-04 Microprobe Corporation Cross-linking oligonucleotides for enzyme-mediated triple strand formation
WO1993009127A1 (en) * 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
WO1993012130A1 (en) * 1991-12-09 1993-06-24 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosines, isoster analogues and isoguanosine derivates and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
F. SEELA: "Palindromic oligonucleotides containing 7-deaza-2'-deoxyguanosine", NUCLEIC ACIDS RES., vol. 14, 1986, pages 2319 - 32 *
F. SEELA: "Poly(adenylic acids) containing the antibiotic tubercidin", NUCLEIC ACIDS RES., vol. 10, 1982, pages 1389 - 97 *
J.F. MILLIGAN: "An anti-parallel triple helix motif with oligodeoxynucleotides containing 2'-deoxyguanosine and 7-deaza-2'-deoxy-xanthosine", NUCLEIC ACIDS RES., vol. 21, 25 January 1993 (1993-01-25), pages 327 - 33 *
M. IKEHARA: "Polynucleotides III.", CHEM. PHARM. BULL., vol. 14, 1966, pages 1338 - 46 *

Also Published As

Publication number Publication date
EP0695306A1 (en) 1996-02-07
AU6632094A (en) 1994-11-08
WO1994024144A2 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6369038B1 (en) Closed antisense and sense oligonucleotides and their applications
US5872105A (en) Single-stranded circular oligonucleotides useful for drug delivery
US6372427B1 (en) Cooperative oligonucleotides
WO2001002423A3 (en) 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith
FI946201A0 (en) Self-stabilized oligonucleotides as therapeutic agents
Praseuth et al. Double helices with parallel strands are formed by nuclease-resistant oligo-[α]-deoxynucleotides and oligo-[α]-deoxynucleotides covalently linked to an intercalating agent with complementary oligo-[β]-deoxynucleotides
US5849900A (en) Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
KR960701077A (en) Oligonucleotide Alkylphosphonate and Alkylphosphonothioate (ALIGLPHOSPHONATES AND ALKYLPHOSPHONOTHIOATES)
FI951600A0 (en) Therapeutic anti-HIV oligonucleotide and drug
ATE460481T1 (en) METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICATION FOR THE THERAPY OF A TUMOR DISEASE
KR960704033A (en) Oligonucleotides with Activity against Humand Immunodeficiency Virus
AU1313095A (en) Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
Bailly et al. The influence of the 2‐amino group of guanine on DNA conformation. Uranyl and DNase I probing of inosine/diaminopurine substituted DNA.
GB2273932A (en) Stable oligonucleotides
HUT66828A (en) Single-stranded circular oligonucleotides
KR100353924B1 (en) Composition and Method for Treatment of CMV Infections
KR960704034A (en) Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and / or Multiplication of Infectious Disease Pathogens
EP0578776A4 (en) Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences.
EP0807172A1 (en) Human immunodeficiency virus transcription inhibitors and methods of their use
RU2008130901A (en) iPHK-mediated inhibition of IGFR for the treatment of ocular angiogenesis
JP2006514546A5 (en)
Yamakawa et al. Properties and anti-HIV activity of nicked dumbbell oligonucleotides
Frauendorf et al. Interaction of linear and folded modified antisense oligonucleotides with sequences containing secondary structure elements
WO2001068147A3 (en) Synthetic oligonucleotides as inducers of erythroid differentiation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1994914131

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994914131

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994914131

Country of ref document: EP